Aethlon Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
August 10, 2023 at 09:15 pm
Share
Aethlon Medical, Inc. reported earnings results for the first quarter ended June 30, 2023. For the first quarter, the company reported net loss was USD 3.28 million compared to USD 2.91 million a year ago. Basic loss per share from continuing operations was USD 1.4 compared to USD 1.9 a year ago.
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.